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Studies on the Storage Stability and Biological 
Variation of Glutathione Peroxidase in Blood Cells and 
Plasma 
SUMMARY Glutathione peroxidase (GSH-Px) is a 
selenium (Se)-dependent enzyme. GSH-Px can be used as a 
tool to assess the Se status of the human body 
especially in those undergoing total parenteral 
nutrition or living in Se-deficient areas. In this 
study, the storage stability and biological variation of 
GSH-Px activity in plasma and red cells were 
investigated. The method for GSH-Px assay was based on 
the coupled assay of Paglia and Valentine (9). Samples 
of plasma, red cells and haemolysate in different 
anticoagulants were stored at different temperatures. 
t found that the enzyme was most stable at -20 C 
and could not be kept at room temperature without 
appreciable change in activity. GSH-Px was more stable 
in red cells than in haemolysates. Citrate was found to 
be better than EDTA -and. heparin retaining GSH-Px 
activity. Serial studies of GSH-Px activity in plasma 
and red cells of 14 healthy subjects provided data on 
biological variation. Samples were drawn on five 
occasions over a period of ten weeks. Different 
components of variation (analytical inter- and 
1 
intraindividual variatipns) were calculated. It was 
found hat the ratio of the average within-subject 





 figure indicating that he conventional 
reference limits of GSH-Px were of limited use and that 
each individual needed his or her own reference interval. 
INTRODUCTION 
Selenium (Se) is firmly established as an essential 
nutrient for humans. Important food sources of Se are 
0
 seafoods, liver, kidney and muscle meats; fruits and 
vegetables are generally low in Se. Grain products vary 
in their Se content, depending on geographical location. 
Low blood levels of the element have been reported in 
individuals from several countries where the soils are 
low in Se, e.g. New Zealand, parts of Finland and China. 
Se deficiency has been suggested as a cause of several 
pathological conditions such as cardiomyopathy, muscle 
pain, muscle weakness and susceptibility to variety of 
drugs and chemicals (1) • One of the most well-known 
problems is the cardiomyopathy known as Keshan disease. 
The mechanism by which Se deficiency allows the 
development of Keshan disease is unknown. Se functions 
as an antioxidant in vivo and one hypothesis is that it 
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prevents oxidant injury of the myocardium. Such damage 
may be due to depletion of oxidant defences alone or 
could be associated with oxidant stresses caused by 
infections or drugs (2) . It has also been shown in 
animals that adequate Se levels protect liver membranes 
against diquat and paraquat poisoning (3). Animals 
deficient in Se had increased susceptibility to liver 
necrosis. Apart from the geographical factors, it has 
been noticed that Se deficiency is associated with 
intravenous hyperalimentation, because Se 
supplementation of parenteral nutrition fluids has not 
been common practice until recently. In 1979, Van Rij 
et al found whole blood Se to be lower in patients on 
parenteral nutrition than in their normal population. 
The deficiency and physiologic consequences of this 
deficiency can be corrected with the administration of 
Intravenous.Se in the form of selenous acid. (4) 
Measurement of Se in blood can be used to monitor 
the Se status of patients receiving total parenteral 
nutrition and of residents of Se deficient areas. 
Historically, determination of Se in biological matrices 
is difficult and tedious. The concentrations present 
are usually below those that can be determined with 
simple flame atomic absorption instruments, making it 
necessary to extract the metal and thus concentrate it. 
3 
Currently, the most commonly used method is graphite 
furnace atomic absorption spectrometry with Zeeman 
background correction which frees the Se determination 
from several interferences such as those iron and 
phosphorus (5) . It would be advantageous if a simpler 
method could be used in the assessment of Se status. 
•In 1973, Se deficiency was found to be associated . 
with glutathione peroxidase (GSH-Px) (EC 1.11.1.9) 
deficiency. GSH-Px was discovered to contain Se in the 
form of selenocysteine. The active site of GSH-Px 
contains one selenocysteine residue inserted in each of 
the enzyme1s four polypeptide chains. GSH-Px plays an 
important role in the detoxification of hydrogen 
peroxide, organic hydroperoxides and lipid peroxides by 
oxidation of reduced glutathione, and thereby protects 
against oxidative damage. . A highly significant 
correlation between body Se concentration and GSH-Px 
activity in whole blood, plasma and erythrocyte has been 
reported. This enzyme may be used as a tool to assess 
the Se status of the' human body especially those 
receiving total parenteral nutrition or those from Se 
deficient areas. Although GSH-Px is Se dependent, there 
is a level of Se above which further increases in its 
availability cause no further elevation of enzyme 
activity V i.e. 1 saturation' occurs (6) . In general, 
. • . 4 
studies of normal, healthy subjects with what is assumed 
to be an adequate intake of Se have failed to find a 
positive correlation between the metal and the enzyme in 
blood or plasma (5) . There have been many studies on 
the Se and GSH-Px levels in plasma and blood cells of 
patients receiving parenteral nutrition or living in Se 
deficient areas. It has been commonly found that Se 
arid GSH-Px levels are significantly lower in those 
people. When the replacement of Se was commenced, there 
was a rapid increase in plasma GSH-Px. Within 6-12 
hours after Se therapy was instituted, there was a 
demonstrable increase in plasma enzyme activity with no 
apparent lag. The recovery rates of red cell and 
platelet GSH-Px activity were similar to their rates of 
production (7)• 
In this project, no further investigations in the 
above aspects were carried out. What was interested 
in were the storage stability and biological variation 
of GSH-Px in blood cells and plasma. The technical 
aspects of GSH-Px assay" will also be discussed. Since 
n6 systematic discussions on the storage stability and 
biological variation of GSH-Px could be found in the 
literature, it was decided to obtain some data in the 
present study• Blood samples collected in different 
anticoagulants (citrate, EDTA and heparin) and stored at 
5 
different temperatures were used in the storage 
stability study. 14 healthy . adults were invited to 
donate blood over a period of 10 weeks, and their data 
were used in the analysis of the biological variation of 
GSH-Px. 
METHODS 
Subjects 14 young and healthy (10 males and 4 
females) laboratory staff were asked to give blood 
samples for the project. They were aged 21-31 years. 
Blood was sampled at 0, 1, 2, 5 and 10 weeks. During 
the 10-week period, the subjects were on a normal diet 
and 10ml of venous blood was taken from each at 9-10 am 
in the morning on each occasion. They were not 
requested to fast and blood was taken after being seated 
for 5 minutes. 
Sample treatment The 10ml blood sample of each 
individual was divided into three different 
anticoagulant bottles : 8ml in citrate (0.9ml '0.106mol/L 
citrate:8ml blood), lml in EDTA (lmg EDTA/ml of blood), 
and lml in heparin (12-15 U/ml of blood) . EDTA and 
heparinized blood samples were centrifuged at 1500g for 
5 minutes to separate red cells from plasma. The former 
6 ‘ 
were washed three times with isotonic saline, and tho 
plasma kept for study. Since platelets can only bo 
extracted from citrated blood, the blood sample in 
citrate was centrifuged at low speed (200g for 10 
minutes) to obtain platelet-rich-plasma (PRP). ThQ 
citrate red cells were also washed throe times with 
isotonic saline. Two additional low spood 
centrifugations of PRP were incorporated to get rid of 
any red cells. The platelets could then be obtained by 
high speed centrifugation (3000g for 15 minutes). The 
platelet pellet was washed three times with isotonic 
magnesium chloride (110 mmol/L). The citrate plasma was 
also kept for further studies. The plasma GSH-Px 
activity in different anticoagulants could be directly 
determined without any special treatment. However, red 
cell and platelet GSH-Px activities could only bo 
assayed after further treatment. 1 part of red cells 
was lysed with 3 parts of 0.02% saponin and bho 
haemolysate then diluted with 10 parts of delonized 
water. After thorough mixing, the 1 in 40 haemolysate 
was centrifuged at 15Q0g for 15 minutes to remove 
debris. The clear supernatant was suitable for assay. 
Sonication has been used to disrupt platelets (8). 
Others have obtained platelet lysates by resuspending 
fresh centrifuged platelet pellets in saturated 
digitonin medium at 4°C for 1 hour and using the 
7 
supernatants to test platelet GSH-Px activity (6) . In 
this project, saponin was investigated as a lysing agent 
for platelets. 0.1% saponin (0.5 ml) was added to each 
platelet pellet and stood overnight at room temperature, 
and the supernatant used for GSH-Px assay. The reason 
for using saponin as a lysing agent was hat it has been 
used satisfactorily in the preparation of platelet 
ly sates for ATPase assay in a project in this 
department (Robertshaw, AM. personal communication). As 
a result, saponin was evaluated to see whether it could 
also be used in the platelet GSH-Px assay. 
Protocol n the storage study, samples of plasma, 
washed red cells and platelet in different 
anticoagulants were obtained from the pooled specimens 
of the first blood taking of 14 volunteers. Moreover, 
haemolysates of red cells were also prepared to compare 
GSH-Px stability in red cell and haemolysate. The 
GSH-Px activities in these various types of specimen 
/ were tested on alternate days during the first two weeks 
and then once a week for, another 3 weeks. 
: .:. : ... , - ' ' •' • : ... • . ..:: -:. .1::.. /::’ ,':.:.:.. - . " - ' .: .:.. -...:-: .. vv . ' - . . . . . . . ' . ' . 
In the biological variation study, blood samples 
obtained on each occasion were processed and GSH-Px 
activities in various blood components were assayed 
within 12 hours. 
8 
The enzyme activity in plasma was expressed as 
international units (1 umol of substrate coverted / 
minute) per litre (U/L) , in red cells as units per gram 
of haemoglobin (U/gHb) and in platelets as units per 
gram of protein (U/g). 
Equipment, reagents and assays In this project, the 
analytical method of GSH-Px assay was based on that 
described by McMaster et al (5) with some modifications. 
The method used by McMaster et al was based on the 
coupled assay of Paglia and Valentine (9). 
For the estimation of enzyme activity in plasma, 
red cells and platelets, the Cobas Bio centrifugal 
analyzer (F. Hoffmann-La Roche & Co. Limited, Balse, 
Switzerland). GSH-Px catalyzes the oxidation of reduced 
glutathione (GSH) by hydrogen peroxide (^C^). The 
substrate is maintained . at a constant concentration by 
the addition of glutathione reductase (GSSG-R) and 
reduced nicotinamide adenine dinucleotide phosphate 
(NADPH). The decrease „ in absorbance of the reaction 
mixture at 340nm is a measure of oxidized glutathione 
(GSSG) production. Therefore, higher GSH-Px activity 
gives greater decrease in absorbance. 
2GSH+H2022-S GSSG+2H20 
+ 
, H++NADPH— — 2GSH+NADP+ 
9 
NADPH tetrasodium salt type 1, glutathione (reduced 
form) and glutathione reductase (EC 1.6.4.2) (type IV) 
were purchased from Sigma Chemical Co. St. Louis, 
U.S.A. 
A litre of the stock phosphate buffer contained 
10.2 g of KH2P 4, 30ml of 0.1 mol/L NafDTA, and 0.4 g 
of NaN3. The pH was brought to 7.0 with a 1 mol/L 
solution of NaOH. The concentration of NaN^ was 1000 
times higher than in the method of McMaster et al. The 
reason for using this concentration of NaN- will be 
* J 
discussed later. 
The enzymatic reaction needed two reagents : the 
principal reagent and start reagent. The principal 
reagent contained 8.67 ml of stock phosphate buffer, 
3.5 mg of NADPH, 10 mg of GSH, 6 U of GSSG-R, and 0.5 ml 
.of Drabkin's reagent. The start reagent contained 34 ul 
of 7.2 mol/L H2 2 in 100 ml of water. Since stock H2 2 
o • is not very stable even at 4 C, its concentration should 
be confirmed monthly by .indirect titration. Because of 
the problem of stability, both reagents were prepared 
'' V 
immediately before use and kept at 4 C in an ice bath. 
The test program for GSH-Px is shown in (Table 1) . A 
100 uL sample was transferred to an analyser cup, and 
the enzyme activity assayed automatically by the 
10, 
Table 2 Cobas Bio test program for haemoglobin 
1• Units u/L 
2. Calculation factor 4019 
3. Standard 1 conc. 0 
4. Standard 2 conc. 0 
5. Standard 3 conc. 0 
6 . Limit 0 . 3300 
7. Temperature (Deg. C) 37 
8• Type of analysis 3 
9. Wavelength (nm) 340 
10. Sample volume (uL) 10 
11. Diluent volume (uL) 20 
12. Reagent volume (uL) 90 
13- Incubation time (sec) 60 
14. Start reagent volume (uL) 10 
15. Time of first reading ( sec) 60.0 
16. Time interval ( sec) 10 
17. Number of readings 7 
18. Blanking mode 1 
19. Printout mode : 2 
11 
computer-controlled instrument. With the test program, 
the sample, diluent, and principal reagent were pipetted 
simultaneously into the analyser rotor and mixed. A 
blank, consisting of reagent and diluent, was 
automatically included. Start reagent (H2 2) was added 
to the cuvettes after incubation of mixture for 60 
seconds at 37°C. After acceleration and mixing, the 
absorbance was read at the pre-programmed time 
intervals. All calculations were based on the change in 
absorbance between readings 1 and 7. The rate of change 
of absorbance for each sample was calculated in 
absorbance units per minute and corrected for the 
corresponding measurement in the blank. The net rate of 
change of absorbance (A a/t) was a measure of the enzyme 
activity. The specific activity of GSH-Px in U/L of 
sample is derived as follows : 
GSH-Px (U/L) = F. Aa/t 
i The calibration factor F was derived from physical 
coefficients, the stoichiometry of the reactions, the 
geometry of the cuvette, and the volume of sample 
introduced into the cuvette. In this protocol, F was 
equal to 4019 (5). 
Enzyme activity in red cells was expressed as 
12 
international units per gram of haemoglobin (U/gHb)• 
Haemoglobin concentration in each haemolysate was 
determined using the Cobas Bio. The reagent and 
haemoglobin standard were supplied by Sigma Chemical Co. 
St. Louis, U.S.A. A vial of Drabkin1s reagent 
(Catalogue No. 525-2) was reconstituted in 400 ml water, 
giving a concentration 2.5 times that of the commonly 
used reagent. 4 ml of concentrated Drabkin's reagent 
was added to a vial of haemoglobin standard (Catalogue 
No. 525-18). This standard was equivalent to 9 gHb/L. 
The linearity of this reaction was from 3-30 gHb/L. 
Table 2 showed the test program for haemoglobin. 
In the platelet assay, the enzyme activity was 
expressed as international units per gram of protein 
(U/g). The protein concentration of the platelet lysate 
was determined with the Bio-Rad procedure in the Cobas 
Bio. This assay is a dye-binding assay based on the 
differential colour change of a dye in response to 
various concentrations of protein. The absorbance 
maximum for an acidic splution of Coomassie Brilliant 
Blue G-250 shifts from 465 nm to 595 nm when binding to 
protein occurs, Beer's Law may be applied for accurate 
quantitation of the protein by selecting an appropriate 
ratio of dye volume to sample concentration. The 
Coomassie Brilliant Blue G-250 was obtained from 
13 
T a b l e 2 C o b a s







- Standard 1 conc.
 9 0 
4. Standard 2 conc.
 9, 0 0 





7. Temperature (Deg. C) 25.0 
8. Type of analysis 
9. Wavelength (nm)
 5 4 0 
10. Sample volume (uL) 
11. Diluent volume (uL) 50 
12. Reagent volume (uL) 90 “ 
13. Incubation time (sec) 10 
14. Start reagent volume (uL) 0 
15. Time of first reading (sec) 0.5 
16. Time interval (sec) 180 
17. Number of readings 10 
18. Blanking mode 1 
19. Printout mode 1 
14 
Bio-Rad Chemical Division, California, U.S.A. One part 
of stock reagent was diluted with four parts of 
deionised water. The standards were prepared by 
diluting the (CSF) calibrator 4 of Astra Systems 
(Beckman Instruments Inc. U.S.A.) with 0.1% saponin. 
The assay was linear over he range 10-220 mg/L. The 
test program for low concentration protein in platelet 
lysate is shown in (Table 3). 
RESULTS 
Technical aspects The method for the GSH-Px assay of 
this project was adopted from the paper of McMaster et 
al (1990) (5) . Reagents were prepared according to 
their description. It was found that there was no 
problem in the reaction of plasma and serum GSH-Px which 
gave enzyme activities of similiar magnitude to other 
reports. However, the enzyme activity in haemolysate 
• could not be determined by the centrifugal analyzer and 
the rate of decrease in absorbance was even smaller than 
** ' 
the blank. The reaction profiles of the enzymatic 
reaction were then investigated. The absorbance 
readings of reaction from time 0 to 190 seconds were 
recalled and plotted on graphs. It was obvious that the 
plasma gave a perfectly linear reaction (Fig. 1), but 
15 , 
Table 2 Cobas Bio test program for haemoglobin 
.
U n i t s mg/L 
2. Calculation factor 0 
3. Standard 1 conc. 0.0001 
4• Standard 2 conc• 52•8 
5. Standard 3 conc. 211.2 
6• Limit 0 
7. Temperature (Deg. C) 25.0 
8• Type of analysis 1 
9. Wavelength (nm) 595 
10. Sample volume (uL) 4 
11. Diluent volume (uL) 20 
12. Reagent volume (uL) 200 
13. Incubation time (sec) 10 
14. Start reagent volume (uL) 0 
15. Time of first reading (sec) 0.5 
16. Tinie interval (sec) 120 
17. Number of readings 2 
18• Blanking mode 1 
19. Printout mode 1 
. . . . . . . ::: . . .::,:.,. .: .:. : : . . : + . : : .:: .. . +. . . . . , . . . . . - . . . . . . . 
16 

the reaction profile of haemolysate was non-linear, the 
absorbance only decreased at the very beginning of 
reaction and then flattened out quickly (Fig. 2) . The 
first reason suspected for non-linearity in the 
haemolysate enzyme assay was the depletion of substrate. 
Therefore, a higher substrate ( NADPH x 2) 
concentration was tried, and the profile was plotted 
(Fig. 3). It was clear that there was no improvement in 
linearity and insufficiency of substrate was unlikely. 
After reading the paper of Paglia and Valentine (9) 
which gave detailed accounts of the quantitative and 
qualitative characterization of erythrocyte GSH-Px, 
further investigations were made. Their method used 
double-strength Drabkin's reagent in the reaction 
mixture / so this was assessed. Unfortunately, the 
reaction was still not linear (Fig. 4) • Increasing 
cyanide concentration (5 times , and 10 times ) was also 
. - • . . ..-. ... • • . • • • • • ....-• . . . ...... • • .•-
studied. It was disappointing that a linear reaction 
could not be observed (Fig. 5). Although those studies 
did not reveal a cause for the non-linearity, another 
was made by increasing azide concentration. Compared 
• ” ... . . • .... . •' • .. .. • •. • •. .. . .... . . . ‘' . .... 
with the reagent compositions quoted in the paper of 
.. "• • .. : ..... . . _ 
Pleban P A et al (10), it was found that all the 
concentrations of reagents were similar in magnitude 
except sodium azide. The sodium azide concentration was 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































finding, buffers of 100 times (0.62 mmol NaN./L 
.. . . • . . . 
phosphate buffer) and 1000 times (6.2 mmol NaN /L 
3 
phosphate buffer) azide were prepared and evaluated. A 
great improvement was now observed, both buffers gave 
nearly linear reaction profiles (Fig. 6) . The new 
buffers were then evaluated for the assay of GSH-Px in 
haemolysates. It was found that buffer of 0.62 mmol/L 
NaN3 gave results with noise while 6.20 mmol/L NaN, 
“ 3 
buffer had perfect results without any noise. The 
buffer containing 6.20 mmol/L NaN3 was therefore chosen 
for the determination of plasma and red cell GSH-Px 
activities in this project. From the above 
observations, it was concluded that the reason of non-
linearity in haemolysate enzyme reaction was due to 
insufficiency of azide in buffer. It is assumed there 
was a misprinting of sodium azide concentration in the 
paper of McMaster et al (5) (i.e. 0 .4 mg/L instead of 
0.4 g/L). 
The platelet lysate could not be successfully 
prepared in this project, therefore no data could be 
provided in the stability and biological variation 
studies. Saponin was evaluated as a lysing agent for 
the platelets where other researchers have used 
sonication or digitonin (6, 7, 8) . Different 

































































































































































































































































































































































































































































































































































































































different methods of resuspension of platelet pellet 
(gently rotary mixing and vortex mixing) and different 
durations of lysing period (20 minutes, 4, 8, 12 or even 
16 hours) were evaluated, but reliable and reproducible 
results could not be obtained. It may be tha saponin 
is not a suitable lysing agent for platelet. Due to the 
constraint of time and availability of chemicals, the 
platelet assay could not be optimized in time for 
inclusion in the project. 
Assay characteristics The centrifugal analyzer used 
for GSH-Px assay was found to be satisfactory. The 
within-run and between-run precisions of enzyme 
activities in plasma and red cells were acceptable, and 
similar to those in other reports (5, 10) . For the 
within-run precision, 25 aliquots of a plasma sample and 
20 or 13 haemolysates of a washed red cells specimen 
were prepared, and then analyzed within the same batch. 
The data of between-run precision were obtained from 
eleven separate runs of the same blood sample. The 
results of precision studies are shown in (Table 4 and 
5) . Obviously, when the coefficients of variance were 
compared, the analytical imprecision of red cell enzyme 
activity was greater than plasma. 
Stability In the literature review, no systematic 
25 
Table 4 Within-run precision of the assay for GSH~Px in 
plasma and red cells 
Sample* n mean+SD CV(%) 
C P
 ( U / L ) 2 5 3 5 8 ± 3 . 8 - 1 
E P ( U / L ) 2 5
 4 3 3 ± 4 . 7 . 1 
HP (U/L) 25 458±6.7 ^ 5 
CR (U/gHb) 20 37.6±2.11 5.6 
E R ( U /g H b ) 2 0 39.7±2.60 • 6.6 
H R
 ( U / _ ) 13 36 .6±1.30 3.6 
* CP = citrate plasma, EP = EDTA plasma, 
HP = heparin plasma, CR = citrate red cells, 
ER = EDTA red cells, HP = heparin red cells 
•. 
26 
Table 5 Between-run precision of the assay for GSH-Px 
in plasma and red cells 
Sample* no. of runs mean SD CV(%) 
CP (U/L) 11 367+10.7 2.9 
EP (U/L) 11 429+16.4 3.8 
HP (U/L) 11 439+11.0 2.5 
CR (U/gHb) 11 38.6+3.72 9.7 
ER (U/gHb) 11 39.7+3.61 ‘ 9 . 6 
HR (U/gHb) 11 42.9+3.26 7.6 
* CP = citrate plasma, EP = EDTA plasma, 
HP == heparin plasma, CR = citrate red cells, 
ER = EDTA red cells, HP = heparin red cells 
27 
discussion on the storage stability of GSH-Px was found. 
In this project, blood samples were collected in three 
different anticoagulants (citrate, EDTA and heparin), 
plasma, washed red cells and red cell haemolysates were 
freshly separated, prepared and aliquoted. These nine 
different types of samples were then stored at three 
different temperatures (room temperature, 4°C and 
-20 C). The enzyme stability in different types of 
specimen, different anticoagulants and at different 
temperatures could be verified in this setting. Table 6 
shows the GSH-Px activities of each type of samples over 
a period of 5 weeks. The stabilities of GSH-Px in 
different types of samples are also shown graphically 
(Figs. 7-15). The percentage of enzyme activity 
remaining after 1 week, 2 weeks and 5 weeks in each type 
of sample is found in (Table 7). 
It is clear that, the enzyme (GSH-Px) deteriorated 
rapidly when stored at room temperature irrespective of 
the type of anticoagulant or specimen. Compared with 
red cells and haemolysates, plasma appears to lose its 
enzyme activity more rapidly at room temperature. 
As expected, -20°C was the most desirable 
temperature for the storage of GSH-Px although there was 
a slight loss in GSH-Px activity after 5 weeks in some 
types of samples. A temperature of 4 C could also keep 
28 
T a b l e 6
 Storage .stability of glutathione peroxidase 
D a y 0 2 4 6 8 10 12 14 21 26 35 
Cit ra te R
. • _ 352 280 222 209 202 137 137 76.2 59.2 69.2 
plasma 4 C 358 365 355 363 362 357 304 315 271 263 184 
( U / L ) '20 C 367 353 361 360 382 354 375 377 378 356 
E D T A R - T ‘ 399 245 162 120 81.8 61.1 57.6 54.7 53.8 52 .4 
plasma 4 C 433 441 416 409 406 397 383 346 231 243 129 
( U / L ) -20 C 438 429 439 448 448 415 435 430 399 404 
Heparin R.T. 398 243 124 81.6 66 .4 59.3 53.7 41.1 45.7 45.3 
P I a s m a 4 C 458 438 395 387 342 226 307 273 189 142 105 
(U/L) , 2 0 C 443 438 419 444 445 438 447 440 435 419 
Citrate R.T. 37.3 23• 15.9 13.3 15.7 13.7 11.8 11.3 10.5 8.67 
h e m 0
. *
 4 c
 37.5 34,2 31.7 34.8 37.4 42.8 34.8 38.5 37.6 30.3 12.9 
(U/g Hb) -20 C 32.0 31.4 34.9 38.6 40.5 34.8 37.0 39.7 32.3 33 .0 
EDTA R.T. _ _ 31.5 17.1 15.5 14.7' 15.5 11.8 12.3 10.9 9.67 M 
hemo. * 4 C 38.7 37.6 35.5 35.1 36.7 42 .0 34.9 37.4 39.0 28.8 19.6 
(U/g Hb) -20 C 35.9 34.8 35.3 35.4 43.7 37.5 35.6 39.1 30.8 30 .4 
Heparin R.T. 38.6 31.3 17.8 14.4 16.7 13.4 1.7 10.9 10.3 8.98 
hemo. * 4 C 41.9 38.3 36.2 36.9 43.6 44.3 37.6 40.2 40.8 31.3 24 .0 
(U/g Hb) -20 C 38.3 37.5 38.8 41.0 42.8 37.3 29.2 42 .4 34.8 31.1 
Citrate R.T. 37,7 34.3 36.4 34.7 27.9 31.7 29.2 23.4 34.3 M 
rbc * 4 C 37.5 38.5 33.3 38.5 38.5 42.6 33.6 36 ,4 34.9 34.0 31.5 
(U/g Hb) -20 C 39.8 36.5 40.4 44.5 46.0 38.1 37.8 34.9 35.3 33.4 
EDTA R.T. 39.9 29.1 27 .0 31.7 23.9 27.1 17.8 12.8 17.7 M 
rbc * 4 C 38.7 41.9 38.7 41.0 41.2 45.9 35.6 35.0 34.5 29.3 31.1 
(U/g Hb) -20 C 41.9 38.7 41.1 43.6 46 .4 39.0 41.4 37.4 34.7 33.3 
Heparin R.T. 43.4 38.0 32.0 34.2 26.5 M M M M M 
rbc + 4 C 41.9 44.2 41 .4 43.3 46.1 49.0 36.7 45.8 38.5 34.7 34.8 
(U/g Hb) -20 C 44.4 41.7 46.3 46.5 48.1 41.9 44 .2 39 .2 38.8 38.8 
* hemo=haemolysate, rbc=red blood cells 
+ M = moulded sample 
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Fig. 19 Effect of storage temperature 
(heparin haemolysate) 
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Fig. 14. Effect of storage temperature 
(EDTA red cells) 
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Fig. 15. Effect of storage temperature 
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Table 7 The percentage of GSH-Px remaining after 
1-weeky 2-week and 5-week 
Sample* T°C + 1-week 2-week 5-week 
CP RT 58 38 19 
4 100 88 51 
-20 100 100 100 
EP RT 28 13 12 
4 94 80 30 
-20 100 100 93 
HP RT 18 12 10 
4 75 60 23 
-20 97 98 91 
CH RT 35 31 23 
4 100 100 34 
-20 100 99 88 
EH RT 38 32 M ^  
4 95 97 51 
-20 91 92 . 79 
HH RT 34 28 21 
4 — 100 96 58 
-20 98 70 74 
CR RT 93 78 M 4 
4 100 97 84 
-20 100 . 100 89 
ER RT 82 46 M 
4 100 90 80 
-20 100 100 86 
HR RT 82 M M 
4 : 100 100 83 
-20 100 100 93 
* CP=citrate plasma, EP=EDTA plasma, HP=heparin plasma, 
CH=citrate haemolysate, EH=EDTA haemolysate, 
HH=heparin haemolysate, CR=citrate red cells, ER=EDTA 
red cells, HR=heparin red cells. 
+ T°C=Temperature, RT=room temperature. • 
M indicates that the specimen was clearly contaminated 
by a growth of mould. 
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the enzyme in plasma quite well for 1 week, except in 
heparin plasma, and even 2 weeks for red cells or 
th 
haemolysates. By the end of 5 week, GSH-Px in plasma, 
haemolysate and red cell lost its activity significantly 
at 4 C. The data show that it is not suitable to store 
the samples for GSH-Px activity at room temperature. 
In the preservation of GSH-Px activity in red cell, 
it appears that the enzyme is more stable in the form of 
washed red cells rather than in the haemolysate. When 
different anticoagulants were compared, it seemed that 
citrate was the best one for preservation of GSH-Px in 
plasma, but its effect on haemolysate or red cell was 
not so marked. The percentage losses of enzyme activity 
in EDTA and heparin samples were quite similar in 
magnitude. 
In the stability study, there was an unexplained 
sudden rise in red cell and haemolysate GSH-Px activity 
on day 10. It may be due to a systematic error, 
although the controls for GSH-Px and haemoglobin did not 
show such a change. However, the plasma samples did not 
have this rise. 
Biological variation In this section of project, 
samples were drawn from 14 volunteers on five occasions 
40 
over a period of ten weeks. It was anticipated that 
there would be variation in the values obtained at 
different times in the one subject. The simplest model 
to be considered was that the variation was random and 
the sources of variation were both analytical and 
biological of a random nature. Blood samples were 
collected in different anticoagulants : citrate, EDTA 
and heparin. The data of plasma and red cell GSH-Px 
activities in different anticoagulants and individuals 
are shown in (Table 8), and (Figs • 16-21) • From the 
data of enzyme activities during the period of 10 weeks, 
there was a significant change in red cell GSH-Px 
activity with time (all three different types of red 
cells had F value greater than 33 and P value less than 
0.0001) . The red cell GSH-Px activity in the second 
s "t 
blood sampling (1 week) was generally higher. Such an 
increase did not occur in plasma samples. Statistically 
significant changes in enzyme activity in citrated and 
heparinised plasma samples with time were found 
(citrate : F=5.57; P=0.0008, heparin : F=3.86 P=0.0078) 
but not in EDTA plasma (F=l.73; P=0.1576). The analysis 
of variance showed there was a significant difference 
between subjects (F values for the subject effect of all 
six types of samples were greater than 17 and P were 
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The mean and SD of each type of specimen are shown 
in (Table 9) . These figures could be used in 
establishing a reference interval for GSH-Px activity. 
Student1s t-test showed that citrate plasma GSH-Px 
activity was significantly lower than heparin- and 
EDTA- plasma levels (P < 0 .0005) , while no statistically 
significant difference between heparin and EDTA plasma 
GSH-Px activities was detected (0.1< P <0.2). A likely 
explanation is that it was due to the dilutional effect 
on the plasma samples caused by the liquid form of 
citrate (1 part citrate to 9 parts blood sample). No 
such difference was found between washed red cell 
GSH-Px activities in the three anticoagulants (P > 0.1). 
To show whether there was difference in GSH-Px 
activites between the sexes, the means of ten males and 
4 females GSH-Px levels (Table 10) were examined by 
Student1 s t-test. In all of the 6 pairs of results, 
there were no statistically significant differences 
between male and female GSH-Px activities. 
• 
One of the major purposes in this study was to find 
the biological variation of GSH-Px in the health. In 
the determination of components of variation, for each 
individual, a single set of data (5 results over a 
period of 10 weeks) was used to calculate the SD, which 
50 :
 r 
Table 9 Mean and SD of GSH-Px activity of 14 subjects 
Sample* Mean SD 
CP.(U/L) 341 52:0 
EP (U/L) 415 55.3 
HP (U/L) 429 59.5 
CR (U/gHb) 35.5 10.23 
ER (U/gHb) 37.7 10.43 
HR (U/gHb) 37.9 9.81 
* CP citrate plasma, EP = EDTA plasma, 
HP = heparin plasma, CR = citrate red cells, 
ER = EDTA red cells, HR = heparin red cells. 
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Table 10 Concentration of GSH-Px activity in plasma and 
red cells in men and women 
men (n=10 ) women (n=4) 
mean (SD) mean (SD) P 
Plasma (U/L) 
Citrate 336(25.5) 354(84.9) 0.1 <P <0.2 
EDTA 414(28.9) 418(100.1) * P^0.5 
Heparin 428(31.7) 432(106.4) P^>0.5 
Red cells (U/gHb) 
Citrate 36.3(10.8) 33.6(3.30) 0.2<P<0.5 
EDTA 38.2(11.2) 36.4(3.52) P>0.5 
Heparin 38.3(11.4) 36.8(3.67) P>0.5 
52 
is made up of analytical imprecision (SD ) and 
intraindividual biological variation (SDT ), 
Intra 
( S D ) 2 ( S D . ) 2 + ( S D t “ 2 A Intra 
the squared SD (variance) being used because variance is 
the statistic which can be mathematically manipulated. 
From the duplicate analyses of each sample, the 
analytical imprecision (SD&) could be calculated using 
the formula SDA = / sum of (differences)2 
N 2 x no• of pairs (11) 
To obtain an estimate of intraindividual biological 
variation, analytical variation had to be deducted from 
the values of SD, (SDT )2 = (SD)2 - (SD,)2. 
Intra A 
Irrespective of the type of anticoagulant, the values 
for SD, analytical imprecision (SD ) and intraindividual 
A 
variation (SDT ) of GSH-Px activities in plasma were 
.intra. 
similar In magnitude. The same was true for the 
different red cell preparations. The means of SD, SD^ 
and SDt ^ of 14 individuals in different types of Intra J^ 
samples are tabulated in (Table 11). It should be 
remarked that the SDA of red cell GSH-Px activity may be 
underestimated because in the analysis of the red cell 
enzyme, haemolysates were assayed in duplicate and the 
data were used in the calculation of SD , but two 
separate haemolysates were not prepared from a red cells 
53 , 
Table 11 Means of SD, SD. and SDT ‘ of GSH-Px 
*. £^  intra 
activity in 14 individuals in different 
samples 
Mean SD Mean SD; Mean SD^ 
A Intra 
Plasma (U/L) 
Citrate 25.8 5.3 25.1 
EDTA 19.1 8 .8 17.5 
Heparin 21.8 7.1 20.4 
Red cells (U/gHb) 
Citrate 5.26 2.06 4.66 
EDTA 4.93 1.89 4.42 
Heparin 2.91 1.10 2.62 
54 
specimen. Therefore, the analytical error associated 
with the preparation of the haemolysates is included in 
Intra 
In a specific type of sample, from the SD _ for 
AJLiJu 
all single sets of data of all subjects (70 data 
points), which was comprised of analytical, 
intraindividual, and interindividual biological 
variation (SDT ^ ) 
Inter 
(SD.r_)2 = (SD.)2 + (SD_ ‘ 2 + (SDt‘ )2 ALL A Intra Inter 
Therefore, the interindividual variation could be 
calculated when all the three parameters were known. 
Table 12 showed these variations. Now, the intra- and 
interindividual variations were available. One of the 
uses of these biological variation figures was the 
assessment of population based reference values. A 
/ J 
ratio could be calculated from : / (SDX , ) / Intra 
J (SDT ‘ 2 (11) V Inter 
If intraindividual biological variation is greater than 
interindividual variation, conventional population based 
reference values will be of value, particularly when 
this ratio is greater than 1.4. However, reference 
values will be of limited use and may give misleading 
impressions especially when the ratio is less than 0.6. 
As shown in (Table 13), all the ratios of different 
types of plasma and red cell GSH-Px activity are less 
55 
T a b l e 1 2 SDALL- S DA SDIntra a n d S Dmter o f 
GSH-Px activity in 14 subjects in different 
samples 
SD 
ALL SDa SDt SDt . 
A Intra Inter 
Plasma (U/L) 
Citrate 52.0 5.3 25.1 45.2 
EDTA 55.3 8.8 17.5
 A 51.7 
Heparin 59.5 7.1 20.4 55.4 
Red cells (U/gHb) 
Citrate 10.23 2.06 4.66 8.87 
EDTA 10.43 1.89 4.42 9.26 
Heparin 9.81 1.10 2.62 9.39 
• . 
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Table 13 The ratio / ( S Di nt r a) 2 o f GSH-Px activity 
J ( S D I n t e r ) 2 
SDIntra SDInter R a t i o 
Plasma (U/L) 
Citrate 25.1 45.2 0.56 
EDTA 17.5 51.7 0.34 
Heparin 20.4 55.4 “ 0 . 3 7 
Red cells (U/gHb) 
Citrate 4.66 8.87 0.53 
EDTA 4.42 9.26 0.48 
Heparin 2.62 9.39 0.28 
• ‘ . 
‘ . • • I • 
,..:.:::... . 57 . 
I 
than 0.6 which implies that the reference intervals of 
GSH-Px in plasma and red cells would be of little use as 
here is a high degree of individuality. (Figs. 22—23) 
DISCUSSION 
The attempt to prepare platelet lysates with the 
use of saponin ended in failure. It may have been due 
to problems in the resuspension and lysis of the 
platelet pellet by saponin. In other researches, 
sonication or digitonin has been used in the lysis of 
platelets. f the instrument for sonication, or the 
chemical digitonin which has also been used were 
available
 f the platelet assay might have been feasible 
and have made this project more informative. 
In the determination of GSH-Px activity in 
haemolysates, several additional chemicals or reagents 
were used. They were Drabkin1s reagent which was 
incorporated with cyanide, and azide. It was believed 
that if Drabkin1 s reagent was not added in the assay 
system, Ho0o would convert oxyhaemoglobin to z z & 
methaemoglobin, allowing NADPH conversion by a direct 
nonenzymatic reaction or through the mediation of 
methaemoglobin reductase. The oxyhaemoglobin in 
58 
Fig. 99 Intraindividual variation in enzyme activity 
(citrate plasma bars represent mean ± 2SD) 
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Fig. 23. Intraindividual variation in enzyme activity 
(citrate/RBC: bars represent means ± 2SD) 
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haemolysate could be converted to the stable 
cyanmethaemoglobin by Drabkin1s reagent and therefore 
the interference with the strict measurement of GSH-Px 
activity was eliminated• Cyanide or azide acted as a 
catalase inhibitor to prevent decomposition of H2 2 by 
red cell catalase in the reaction system. The cyanide 
contributed by the Drabkin's solution was found 
insufficient in concentration to inhibit totally the 
endogenous catalase. Addition of azide was necessary to 
reach the catalase-blocking level. Since the activity 
of GSH-Px appears to be dependent upon active sulfhydryl 
groups and was unaffected by low concentrations of 
azide, cyanide or ferricyanide, the GSH-Px activity in 
plasma sample could also be measured with reagent 
incorporated with these components (9) . The problem of 
non-linearity in the haemolysate assay using reagents 
suggested by McMaster et al (5) was due to the 
insufficiency of azide in the reaction system and . 
failure to suppress the endogenous catalase. After 
increasing the azide concentration a thousand fold, a 
nearly linear reaction profile could be obtained. 
No report could be found giving a detailed 
discussion on the storage stability of GSH-Px at 
different temperatures and in different anticoagulants. 
nformation in this area sought in this study. Like 
61 
other enzymes, GSH-Px was best preserved at low 
temperature (-20oC), and was unstable at room 
temperature. The enzyme activity in plasma at -20°C in 
general did not drop significantly at least for 4-5 
weeks. In haemolysate and red cell, GSH-Px could be 
kept for at least 3 weeks at -20°C. It was interesting 
that at 4°C the enzyme in haemolysate and red cell was 
quite stable for about 3 weeks, but not in plasma. 
Among the three anticoagulants, it was found that 
citrate was apparently better than the other wo in 
keeping GSH-Px activity especially in plasma sample, 
because the percentage drops in enzyme activity of 
samples stored at different temperatures were 
comparatively smaller. However, the activity of GSH-Px 
in citrate plasma was significantly lower, which may 
have been due to the dilution effect contributed by the 
liquid form of citrate. Compared with the red cell, the 
enzyme was not as stable in haemolysates. As a result, 
and in order to preserve intracellular GSH-Px in blood 
cell, it is considered best to keep the washed red cells 
at -20°C, , 
The analysis of variance showed that except in EDTA 
plasma, there were statistically significant changes of 
GSH-Px activity in both red cells and plasma with time. 
The changes in red cell samples were much greater than 
‘ 62 
‘ 
the plasma samples. This might have been due to the 
generally higher levels in red cell enzyme activity in 
the second blood sampling (week 1). We cannot exclude 
some other factors such as environmental and seasonal 
changes as the causes for this increase. It appears 
more likely that the analysis of variance has detected a 
systematic analytical variation that was not apparent 
from the results of quality control specimens assayed at 
the time. However, the significant changes in plasma 
enzyme activity might indicate that GSH-Px activity does 
fluctuate with time due to environmental effects and 
etc . 
Changes in numerical laboratory results can occur 
with time following acute disease processes, 
physiological or pharmacological stimulation or 
suppression. Moreover, marked changes happen over a 
lifetime, especially during the neonatal period and 
childhood and in the elderly. Some body constituents 
show regular rhythmic changes which may be daily, 
monthly or seasonal in nature. It is important to know 
these changes otherwise specimens may not be collected 
at appropriate times, wrong reference values may be used 
and correct interpretation of test results cannot be 
achieved. Most analytes do not exhibit rhythmical 
variation but rather show random variation which is due 
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to two sources : analytical imprecision and biological 
variation. The biological variation around the 
homeostatic setting-point in an individual is called the 
intraindividual variation and the differences between 
the setting-points of individuals is called the 
interindividual variation. Schneider found : "No matter 
how finely we restrict a group of healthy persons by 
age, sex and other criteria, and no matter how narrowly 
we restrict our observations in the same individual with 
respect to time of day/ relation to meals and 
physiologic conditions, in general we are left with 
unexplained variability from time to time and from 
person to person." (12) . Analytical variation is mainly 
contributed by the inconsistency in collecting the 
specimen, processing of the specimenarid subsequent 
analysis. The intra-individual biological variation may 
be influenced by several factors such as diurnal effect, 
hormones, posture, diet, exercise and seasonal changes. 
Age / sex, race, environment, genetics, stress and 
medication are believed to be important factors that 
influence interindividual variation. 
Biological variation data can be used in patient 
care to assess the significance of changes in serial 
results obtained on an individual, to determine the 
usefulness or otherwise of conventional population based 
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reference values and to set desirable standards of 
analytical performance. The biological variation of 
GSH-Px in young healthy subjects was investigated in 
this study and the data applied to the various uses 
mentioned above. 
In the study, the 14 healthy volunteers were not 
constrained in any aspect of their lifestyles and were 
not on any drugs. Blood samples were taken at the same 
time of day to eliminate variations caused by circadian 
rhythms. However, they were not requested to fast 
before blood sampling and their physical activity, and 
stress levels were not known. f these parameters were 
controlled, the pre-analytical variation would have been 
further minimized. 
One of the uses of biological variation data is to 
establish whether two test results from a single patient 
are statistically significantly different. It can be 
based upon the SD of the test which includes analytical 
random variation and „ biological variation, where 
. SD = / (SD i l • 2 + (SD, .
 n . i ) • If the value 
V analytical biological 
of dif ference between two test results is about 2.8 
times of SD, it can be claimed that it is 95% certain 
that two results differ• deally, clinical laboratories 
can provide data about biological variation and 
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analytical variation achieved in their own laboratory 
and give this information to the clinicians so hat 
better interpretation of numerical data can be made with 
good knowledge of both relevant analytical and 
biological variation (11). 
The ratio (SDintra) 2 / ( SDInter} 2 1 ^^  Provides an 
_ _ I • 
index for judging whether the conventional 
population-based reference range is likely to detect a 
statistically significant change within a given 
individual. Briefly, when this ratio is less than Q.6, 
the reference range will be less sensitive to change 
than the individual1s own record of test measurements 
during the past. The 95% reference range derived from a 
large group may include a greater-than-95% proportion of 
the individual's distribution of values over a period of 
time. It will not be of significant help to 
interpretation because individuals may have marked 
changes with constituent levels significantly different 
from their own usual values but all these results may 
still lie within the us,ual reference interval. On the 
other hand, if intraindividual biological variation is 
greater than intraindividual variation, and particularly 
when the ratio exceeds 1.4, conventional population 
based reference values will be of value. Generally, the 
95% reference range includes less than 95% of the 
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individual's usual distribution of values. However, for 
subjects in whom the concentration of a serum 
constituent is kept within a relatively narrower values, 
the population-based range remains less sensitive to 
charges (13)• Using the ratio of average within-subject 
variance to the variance among subjects as a guide, both 
plasma and red cell GSH-Px activities showed great 
individuality, the population-based reference range for 
GSH-Px was found to be either insensitive or irrelevant. 
It is not surprising to have reference range of 
common clinical tests which are found to be of limited 
use. In the study by Harris E.K. et al (14), the 
usefulness of reference ranges of laboratory tests 
(renal function test, liver function test, glucose, 
calcium phosphate and cholesterol) were investigated. 
It was found that even including analytical variation, 
12 of the 18 ratio :
 n t r a )'/ ( SD I n t e r) 2 values 
were less than unity. In five of the six remaining 
tests (sodium, potassium, carbon dioxide, calcium,. and 
AST in women), the normal range was of marginal validity 
in terms of intraindividual variation (1.2< r-<.1.4). 
Therefore, the population-based range would be regarded 
as insensitive to individual changes. The implication 
is clear that routine assessment of individual 
laboratory tests by reference to conventional, 
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population-based normal ranges should no longer remain 
an accepted, automatic practice. In at least some 
tests, individual normal ranges may be necessary for 
reliable interpretation of results. 
It is generally accepted that the goals for 
imprecision should be based upon biological variation. 
Low analytical imprecision will be required if 
biological variation around the homeostatic 
setting-point is small. The tolerable analytical 
variability should be equal to or less than one half the 
relevant biological variation. (11) 
^
Panalytical lSDIntraindividual 
Referring to table 12, it may be claimed that the 
analytical goals for the performance characteristics of 
GSH-Px assay are achieved because the SD^ values were 
much lower than half of SDT , values. 
Intra 
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